GT200500020A - Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. - Google Patents

Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.

Info

Publication number
GT200500020A
GT200500020A GT200500020A GT200500020A GT200500020A GT 200500020 A GT200500020 A GT 200500020A GT 200500020 A GT200500020 A GT 200500020A GT 200500020 A GT200500020 A GT 200500020A GT 200500020 A GT200500020 A GT 200500020A
Authority
GT
Guatemala
Prior art keywords
tieno
pirazol
useful
derivatives
quinase
Prior art date
Application number
GT200500020A
Other languages
English (en)
Inventor
Daniele Fancelli
Simona Bindi
Mario Varasi
Paola Vianello
Sergio Vioglio
Dania Tesei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500020A publication Critical patent/GT200500020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

SE REVELAN DERIVAOS DE TIENO[2,3C]PIRAZOL DE FORMULA (I) Y SALES DE LOS MISMOS ACEPTABLES PARA USO FARMACEUTICO, SEGUN SE DEFINIO EN LA MEMORIA DESCRIPTIVA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN; LOS COMPUESTOS DE LA INVENCION PUEDEN SER UTILES EN TERAPIA, EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON UNA MALA REGULACION DE LA ACTIVIDAD DE LA PROTEINA QUINASA, COMO POR EJEMPLO CANCER.
GT200500020A 2004-02-03 2005-02-03 Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. GT200500020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54145204P 2004-02-03 2004-02-03

Publications (1)

Publication Number Publication Date
GT200500020A true GT200500020A (es) 2005-09-06

Family

ID=34837492

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500020A GT200500020A (es) 2004-02-03 2005-02-03 Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.

Country Status (38)

Country Link
US (2) US8138217B2 (es)
EP (1) EP1711177B1 (es)
JP (1) JP4908233B2 (es)
KR (1) KR20060124734A (es)
CN (1) CN1946395B (es)
AP (1) AP2006003701A0 (es)
AR (1) AR047531A1 (es)
AT (1) ATE396724T1 (es)
AU (1) AU2005210114B2 (es)
BR (1) BRPI0507375A (es)
CA (1) CA2555262C (es)
CR (1) CR8546A (es)
CY (1) CY1108246T1 (es)
DE (1) DE602005007181D1 (es)
DK (1) DK1711177T3 (es)
DO (1) DOP2005000014A (es)
EA (1) EA011032B1 (es)
EC (1) ECSP066767A (es)
ES (1) ES2307144T3 (es)
GE (1) GEP20094633B (es)
GT (1) GT200500020A (es)
HK (1) HK1101343A1 (es)
IL (1) IL177141A0 (es)
MA (1) MA28429B1 (es)
MX (1) MXPA06008787A (es)
NO (1) NO20063768L (es)
NZ (1) NZ548896A (es)
PA (1) PA8622801A1 (es)
PE (1) PE20051095A1 (es)
PL (1) PL1711177T3 (es)
PT (1) PT1711177E (es)
SI (1) SI1711177T1 (es)
TN (1) TNSN06244A1 (es)
TW (1) TW200526204A (es)
UA (1) UA86223C2 (es)
UY (1) UY28738A1 (es)
WO (1) WO2005074922A1 (es)
ZA (1) ZA200606179B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250040A1 (en) * 2002-07-25 2004-02-23 Pharmacia Italia S.P.A Condensed heterocyclic pyrazole derivatives as kinase inhibitors
WO2007009898A1 (en) * 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
CA2624795A1 (en) * 2005-10-06 2007-04-12 Merck Sharp & Dohme Limited Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE524177T1 (de) * 2006-03-30 2011-09-15 Nerviano Medical Sciences Srl Verwendung eines kinasehemmers zur behandlung von bestimmten resistenten tumoren
DE602007008736D1 (de) 2006-05-31 2010-10-07 Nerviano Medical Sciences Srl 1h-furoä3,2-cü pyrazolverbindungen, die sich als kinaseinhibitoren eignen
FR2904626B1 (fr) 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
KR100923540B1 (ko) 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
AR071780A1 (es) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
EP2411001B1 (en) * 2009-03-23 2018-01-17 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
JP6314128B2 (ja) * 2012-04-05 2018-04-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 新たなアルキル化剤
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
BR112020010905A2 (pt) * 2017-11-30 2020-11-17 Hanmi Pharm. Co., Ltd. compostos, composição farmacêutica e uso de um composto ou da composiçao farmacêutica
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234622B1 (en) 1986-02-19 1990-06-27 Duphar International Research B.V New thio compounds having fungicidal activity
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA005373B1 (ru) 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
HU229824B1 (en) * 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
JP2004519486A (ja) 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー クロマン誘導体、その製造方法及びその抗腫瘍剤としての使用
JP4542338B2 (ja) 2001-09-26 2010-09-15 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
EP1506176B1 (en) * 2002-05-17 2013-04-24 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BR0312722A (pt) * 2002-07-17 2005-05-10 Pharmacia Italia Spa Derivados de pirazol heterobicìclico como inibidores de qinase
AU2003250040A1 (en) * 2002-07-25 2004-02-23 Pharmacia Italia S.P.A Condensed heterocyclic pyrazole derivatives as kinase inhibitors
US20050026984A1 (en) * 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products

Also Published As

Publication number Publication date
IL177141A0 (en) 2006-12-10
HK1101343A1 (en) 2007-10-18
CA2555262C (en) 2014-10-14
TNSN06244A1 (fr) 2007-12-03
CN1946395B (zh) 2014-04-02
UA86223C2 (uk) 2009-04-10
CN1946395A (zh) 2007-04-11
CR8546A (es) 2007-05-30
PL1711177T3 (pl) 2008-11-28
BRPI0507375A (pt) 2007-07-10
ES2307144T3 (es) 2008-11-16
WO2005074922A1 (en) 2005-08-18
TW200526204A (en) 2005-08-16
PE20051095A1 (es) 2005-12-31
AP2006003701A0 (en) 2006-08-31
ATE396724T1 (de) 2008-06-15
UY28738A1 (es) 2005-09-30
DOP2005000014A (es) 2006-08-15
AR047531A1 (es) 2006-01-25
MA28429B1 (fr) 2007-02-01
EA011032B1 (ru) 2008-12-30
EP1711177B1 (en) 2008-05-28
PT1711177E (pt) 2008-09-04
CA2555262A1 (en) 2005-08-18
AU2005210114B2 (en) 2011-07-14
US8138217B2 (en) 2012-03-20
NZ548896A (en) 2010-05-28
MXPA06008787A (es) 2007-01-19
ECSP066767A (es) 2006-11-24
US8481584B2 (en) 2013-07-09
NO20063768L (no) 2006-11-02
DE602005007181D1 (de) 2008-07-10
US20120165311A1 (en) 2012-06-28
JP2007520513A (ja) 2007-07-26
US20050187209A1 (en) 2005-08-25
KR20060124734A (ko) 2006-12-05
EP1711177A1 (en) 2006-10-18
GEP20094633B (en) 2009-03-10
SI1711177T1 (sl) 2008-10-31
DK1711177T3 (da) 2008-09-29
PA8622801A1 (es) 2005-11-25
ZA200606179B (en) 2008-02-27
EA200601418A1 (ru) 2006-12-29
AU2005210114A1 (en) 2005-08-18
CY1108246T1 (el) 2014-02-12
JP4908233B2 (ja) 2012-04-04

Similar Documents

Publication Publication Date Title
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
CU20060152A7 (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación
UY27315A1 (es) Pirimidinas inhibidoras de cdk, su preparación y uso como medicamento.